Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ERAS Erasca
4.000+0.030+0.76%
Close
01/31 16:00 ET
4.0000.0000.00%
Post Mkt Price 01/31 16:26 ET
High
4.110
Open
3.970
Turnover
5.26M
Low
3.930
Pre Close
3.970
Volume
1.31M
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Insiders Might Want to Re-evaluate Their US$658k Stock Purchase as Erasca, Inc. (NASDAQ:ERAS) Drops to US$572m
Insiders who acquired US$658k worth of Erasca, Inc.'s (NASDAQ:ERAS) stock at an average price of US$4.38 in the past 12 months may be dismayed by the recent 8.4% price decline. Insiders buy with the
Comparing Erasca (NASDAQ:ERAS) and Longboard Pharmaceuticals (NASDAQ:LBPH)
Longboard Pharmaceuticals (NASDAQ:LBPH – Get Rating) and Erasca (NASDAQ:ERAS – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses base
We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersShuttle Pharmaceuticals (NASDAQ:SHPH) stock rose 17.5% to $2.08 during Thursday's after-market session. At the close, Shuttle Pharmaceuticals's trading volume reached 565.4K shares. This is 40.
Over $4 Million Bet On Werewolf Therapeutics? Check Out These 4 Penny Stocks Insiders Are Buying
The Dow Jones closed higher on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks
HALO, GOOD and TCOM Are Among After Hours Movers
Stocks That Hit 52-Week Lows On Tuesday
 Tuesday's session saw 16 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: The company with the largest market cap to set a new 52-week low was Pacira BioSciences (NASD
Erasca to Present at the 41st Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for
Erasca (NASDAQ:ERAS) Trading 3.4% Higher
Shares of Erasca, Inc. (NASDAQ:ERAS – Get Rating) traded up 3.4% on Friday . The company traded as high as $4.33 and last traded at $4.26. 19,904 shares traded hands during mid-day trading, a decline
Red Cat Holdings And 2 Other Penny Stocks Insiders Are Aggressively Buying
The Dow Jones settled higher by around 175 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or conce
Company Overview
More
Erasca, Inc. is a clinical stage precision oncology company, It focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim on July 2, 2018 and is headquartered in San Diego, CA.
CEO： Dr. Jonathan E. Lim,M.D.
Market： NASDAQ
Listing Date： 07/16/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet